TEMPO.CO, Jakarta - President Director of local pharmaceutical company Kalbe Farma, Vidjongtius, officially announced the price for the antiviral drug Covifor or Remdesivir for the use in Covid-19 patients.
The drug procurement was in collaboration with Amarox Pharma Global, a subsidiary of one of India’s leading generic pharmaceutical firms, Hetero.
“The price is set around Rp3 million per dose, and it depends on the volume,” said Vidjongtius in Jakarta, Thursday, October 1, 2020. He added that the price would subject to change if there is an increase in volume demand.
In the drug procurement, Kalbe Farma took a role in the marketing and the distribution. Meanwhile, the drug was manufactured by Hetero at its facilities in India.
According to the Kalbe Farma CEO, Amarox Pharma Global had received the Emergency Use Authorization (EUA) approval for the Remdesivir from the Indonesian Food and Drug Authority or BPOM.
Vidjongtius went on to say that his company did not limit the investment value prepared for the procurement of the Covid-19 drug.
“As for the investment, for us in Kalbe, this is more than just procuring imported goods from India. So we do not limit how much investment we prepare. This is more about working capital,” he said.